rdf:type |
|
lifeskim:mentions |
umls-concept:C0006823,
umls-concept:C0010186,
umls-concept:C0011860,
umls-concept:C0030705,
umls-concept:C0220812,
umls-concept:C0332307,
umls-concept:C0537270,
umls-concept:C0870071,
umls-concept:C0907402,
umls-concept:C0920317,
umls-concept:C0936012
|
pubmed:issue |
2
|
pubmed:dateCreated |
2011-3-22
|
pubmed:abstractText |
Two basal insulin analogues, insulin glargine once daily and insulin detemir once or twice daily, are marketed in Canada. Objective: To estimate the long-term costs of insulin glargine once daily (QD) versus insulin detemir once or twice daily (QD or BID) for type 1 (T1DM) and type 2 (T2DM) diabetes mellitus from a Canadian provincial government's perspective.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1941-837X
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
207-16
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:21361858-Cost-Benefit Analysis,
pubmed-meshheading:21361858-Diabetes Mellitus, Type 1,
pubmed-meshheading:21361858-Diabetes Mellitus, Type 2,
pubmed-meshheading:21361858-Female,
pubmed-meshheading:21361858-Health Care Costs,
pubmed-meshheading:21361858-Hemoglobin A, Glycosylated,
pubmed-meshheading:21361858-Humans,
pubmed-meshheading:21361858-Hypoglycemic Agents,
pubmed-meshheading:21361858-Insulin,
pubmed-meshheading:21361858-Insulin, Long-Acting,
pubmed-meshheading:21361858-Male,
pubmed-meshheading:21361858-Markov Chains,
pubmed-meshheading:21361858-Models, Economic,
pubmed-meshheading:21361858-Risk
|
pubmed:year |
2011
|
pubmed:articleTitle |
Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
|
pubmed:affiliation |
IMS Health, London, UK. aguillermin@uk.imshealth.com
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Meta-Analysis
|